Services for CAR-T Cells - Commercial grade

CAR-T (Chimeric Antigen Receptor T Cell) therapy leverages the patient’s own T lymphocytes, which are genetically modified in the laboratory to express receptors that specifically target tumor antigens. These engineered cells are then expanded ex vivo and reinfused into the patient, enabling them to identify and eliminate tumor cells. Apex specializes in offering comprehensive service solutions for cellular therapies. The company has developed a fully closed process development platform for cellular therapies, allowing it to deliver high-quality, customized services to clients with diverse needs in cell-based treatments.

Services

Advantages

Advantages of our Platform:

• Proprietary cryopreserved cell preparation

• Closed, automated culturing systems, aligned with global standards

• GMP-compliant facilities with B+A grades and unidirectional airflow

• Enhanced cell proliferation rates, improving growth and positive rates

• Flexible for various cellular therapies

• Extensive experience with automated culturing equipment

• Manufactured 200+ IIT clinical samples

• Successful CAR-T IND submission approved by NMPA

• Expertise in technology transfer and clinical cell sample manufacturing

Manufacturing Process

Quality Control